South Korea-based ADEL said late on Monday that it has entered a $1.04 billion partnership with French drugmaker Sanofi to ...
Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysemaAdditional orphan designation ...
Following the disappointment of a multiple sclerosis (MS) trial readout this week, Sanofi has signed a pair of deals in the ...
Sanofi (EURONEXT: SAN) announced Wednesday that its investigational therapy, efdoralprin alfa, has received orphan drug ...
ADEL-Y01, a monoclonal antibody targeting tau protein, is in Phase I trials for Alzheimer's disease, developed by ADEL and ...
Paris, France – December 17, 2025. Sanofi announced today that its Q4 2025 Aide memoire is available on the "Investors" page of the company's website: Fourth quarter & full year 2025 results ...
Sanofi will not be pursuing approval of tolebrutinib for PPMS, and an FDA decision on the therapy in nonrelapsing SPMS will ...
Discusses Year-End Late-Stage Pipeline Review With Focus on Clinical and Regulatory Developments December 16, 2025 11:15 AM ...
Fintel reports that on December 15, 2025, JEFFERIES maintained coverage of Sanofi (OTCPK:SNYNF) with a Buy recommendation. Analyst Price Forecast Suggests 29.28% Upside As of November 17, 2025, the ...
Clinical Trials Arena on MSN
Sanofi shares fall 6% after double setback for MS drug tolebrutinib
The FDA has delayed tolebrutinib’s review date again, as Sanofi also posted a Phase III failure for the MS candidate.
Investing.com -- Sanofi (EURONEXT:SAN) said Wednesday that its investigational therapy efdoralprin alfa has received orphan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback